藥物交互作用
Nivolumab + Ponesimod
嚴重程度: 中度
Nivolumab and Ponesimod: moderate interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
用白話說明這項交互作用的意義
Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
為什麼會發生
Ponesimod sequesters lymphocytes in lymphoid tissue via S1P receptor modulation, which may counteract the T-cell activation sought with PD-1 blockade.
處置方式
Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
可向藥師詢問的問題
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Nivolumab 的其他交互作用
Ponesimod 的其他交互作用
常見問題
Can I take Nivolumab with Ponesimod?
MediHelp rates the interaction as moderate. Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
How serious is the interaction between Nivolumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
